Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
暂无分享,去创建一个
B. Konkle | D. Bevan | O. Stasyshyn | M. Shima | B. Abbuehl | B. Ewenstein | W. Engl | P. Chowdary | T. Mant | J. Dyck-Jones | Monika Fuerlinger | L. Patrone
[1] G. Spotts,et al. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method , 2014, Biologics : targets & therapy.
[2] J. Dumont,et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.
[3] J. Windyga,et al. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] C. Kempton,et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. , 2013, Blood.
[5] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] L. Valentino,et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.
[7] P. Fogarty,et al. Biological rationale for new drugs in the bleeding disorders pipeline. , 2011, Hematology. American Society of Hematology. Education Program.
[8] H. Ehrlich,et al. BAX 855, a PEGylated rFVIII product with prolonged half-life , 2011, Hämostaseologie.
[9] D. Lillicrap. Improvements in factor concentrates , 2010, Current opinion in hematology.
[10] P. Giangrande,et al. Psychometric evaluation of a patient‐reported symptom assessment tool for adults with haemophilia (the HAEMO‐SYM) , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] S. Jönsson,et al. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.
[12] G. Spotts,et al. Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients , 2008, Journal of thrombosis and haemostasis : JTH.
[13] Alan R. Cohen,et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.
[14] A. Shapiro,et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1 , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] S. Björkman. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[16] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[17] E. Gomperts,et al. A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A , 1997, Thrombosis and Haemostasis.
[18] J. T. ten Cate,et al. Inter‐individual variation in half‐life of infused recombinant factor VIII is related to pre‐infusion von Willebrand factor antigen levels , 1995, British journal of haematology.
[19] H. Ehrlich,et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. , 2009, Expert opinion on biological therapy.
[20] E. Gomperts,et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. , 1997, Thrombosis and haemostasis.